2012-10-10 21:37:44 - New Pharmaceuticals market report from Global Markets Direct: "MediGene AG - Product Pipeline Review - 2012"

Global Market Direct's pharmaceuticals report, "MediGene AG - Product Pipeline Review - 2012" provides data on the MediGene AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, MediGene AG's corporate website, SEC filings, investor presentations and featured press releases, both from MediGene AG and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* MediGene AG - Brief MediGene AG overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of MediGene AG human therapeutic division.
* Overview of pipeline therapeutics

across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of MediGene AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the MediGene AG's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468559_medigene_ag_product_pipeline_review_2 ..


Reasons to buy

* Evaluate MediGene AG's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of MediGene AG in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the MediGene AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with MediGene AG.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of MediGene AG and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
MediGene AG Snapshot
MediGene AG Overview
Key Information
Key Facts
MediGene AG - Research and Development Overview
Key Therapeutic Areas
MediGene AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
MediGene AG - Pipeline Products Glance
MediGene AG - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
MediGene AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
MediGene AG - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
MediGene AG - Drug Profiles
Adeno-Associated Virus-Like Particles
Product Description
Mechanism of Action
R&D Progress
EndoTAG-1 + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
L1 Monoclonal Antibody
Product Description
Mechanism of Action
R&D Progress
liposomal paclitaxel
Product Description
Mechanism of Action
R&D Progress
RhuDex
Product Description
Mechanism of Action
R&D Progress
Veregen
Product Description
Mechanism of Action
R&D Progress
MediGene AG - Pipeline Analysis
MediGene AG - Pipeline Products by Therapeutic Class
MediGene AG - Pipeline Products by Route of Administration
MediGene AG - Pipeline Products By Mechanism of Action
MediGene AG - Recent Pipeline Updates
MediGene AG - Dormant Projects
MediGene AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
etomoxir
MediGene AG - Company Statement
MediGene AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
MediGene AG, Recent Developments
MediGene AG- Press Release
Jul 02, 2012: Medigene's Veregen Receives Marketing Authorization In France
Jun 21, 2012: Medigene Achieves Positive Formulation Study Results For RhuDex For Treatment Of Autoimmune Diseases
Jun 05, 2012: Medigene Announces Launch Of Veregen In Spain
May 31, 2012: Medigene's Veregen Receives Market Approval In Serbia
May 02, 2012: Medigene Obtains US Patent For EndoTAG-1 For Treatment Of Triple-Negative Breast Cancer
Apr 10, 2012: Medigene Presents Preclinical AAVLP Data At World Vaccine Congress
Mar 30, 2012: Medigene's Veregen Obtains Market Approval In Switzerland
Mar 08, 2012: MediGene's Veregen Receives Positive Decision On Marketing Approval For 17 Additional European Countries
Jan 25, 2012: MediGene Initiates Clinical Formulation Study Of RhuDex For Oral Treatment Of Autoimmune Diseases
Oct 09, 2009: MediGene Successfully Completes Patient Recruitment Into EndoTAG-1 Phase II Breast Cancer Trial
Oct 09, 2009: MediGene Successfully Completes Patient Recruitment Into EndoTAG-1 Phase II Breast Cancer Trial
Oct 05, 2009: Active Biotech's RhuDex Clinical Development To Continue Following Feedback From Regulatory Authorities
Oct 05, 2009: RhuDex(TM) Clinical Development To Continue Following Feedback From Regulatory Authorities
Aug 07, 2009: Active Biotech Presents Information Regarding The Candidate Drug RhuDex(TM)
Financial Deals Landscape
MediGene AG, Deals Summary

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468559&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.